Zimmer Biomet

PM360 Magazine Announces Winners of 2022 Trailblazer Awards

Retrieved on: 
Friday, September 23, 2022
People, Trailblazer, Creativity, Kidney disease, Industry, Overactive bladder, Patient, Horizon Therapeutics, Chief executive officer, Technology, Amgen, Leadership, PR, Communication, Zimmer Biomet, Gerald Loeb Lifetime Achievement Award winners, Brand, Heart failure, Character, GoodRx, Culture, Boehringer Ingelheim, Tennis, Social responsibility, Morality, Degenerative disease, CEO, AMVCA Trailblazer Award, List of lifetime achievement awards, Snow, Marketing, FCB (advertising agency), Wishbone, Diversity, CRISPR, Medicine, Michaelson, Lung cancer, Decision-making, 360, Education, Novo Nordisk, Pharmaceutical industry, Management, Public relations, Fine chemical, Year, Calcium, Narcolepsy, Greenwich Savings Bank Building, Organon

NEW YORK, Sept. 23, 2022 /PRNewswire/ -- PM360, a leading life sciences marketing industry trade publication, announced the winners of their 14th annual Trailblazer Awards during an event held at Gotham Hall in New York City on Thursday, September 22, 2022. The awards recognize outstanding companies, CEOs, products, marketers, brand managers, and cutting-edge initiatives within the pharmaceutical, biotech, medical device, and diagnostics industries. In total, 72 winners were named across eight overall categories: Companies of the Year, CEOs of the Year, Products of the Year, Marketer of the Year, Marketing Team of the Year, Lifetime Achievement, Brand Champions, and Initiatives.

Key Points: 
  • NEW YORK, Sept. 23, 2022 /PRNewswire/ -- PM360, a leading life sciences marketing industry trade publication, announced the winners of their 14th annual Trailblazer Awards during an event held at Gotham Hall in New York City on Thursday, September 22, 2022.
  • The awards recognize outstanding companies, CEOs, products, marketers, brand managers, and cutting-edge initiatives within the pharmaceutical, biotech, medical device, and diagnostics industries.
  • Each of the winners were judged and selected by the PM360 Editorial Advisory Board, a cross section of experts from across the industry.
  • PM360 will publish profiles of this year's Trailblazer winners in its October issue and on its website.

Pulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation

Retrieved on: 
Tuesday, September 20, 2022
Biotechnology, Health Technology, Health, Medical Devices, NPS, Zimmer Biomet, Time, Safety, Engineering, Zimmer, Director, Company, Health, Growth, List of life sciences, Business, U.S. Securities and Exchange Commission, Patient, Johnson & Johnson, Dermatology, Gastroenterology, Physician, Technology, Quality of life, Solution, Nasdaq, Medtronic, Leadership, Tufts University, Board, Â, Security (finance), Marketing, Business development, Board of directors, Intuitive Surgical, Management, Medical imaging, Science, Pulse

I am confident in NPS technology and its potential, said Robert Duggan, Executive Chairman of Pulse Biosciences.

Key Points: 
  • I am confident in NPS technology and its potential, said Robert Duggan, Executive Chairman of Pulse Biosciences.
  • Implementing the present time strategic opportunities does not require the significant sales, marketing and related administrative support team that has been in place.
  • Accordingly, headcount now stands at 66 employees principally focused on engineering, business development and related new product support personnel.
  • Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Zimmer Biomet Receives FDA Clearance for Identity™ Shoulder System for Shoulder Replacement

Retrieved on: 
Tuesday, September 20, 2022
Sports medicine, Health, Culture, College of Physicians and Surgeons, Department, Twitter, NYSE, FDA, Food, Columbia University, Intention, Life, Orthopedic surgery, News, Private Securities Litigation Reform Act, List of colleges of physicians, Forward-looking statement, Patient, U.S. Securities and Exchange Commission, Pain, Rotation, Physician, Solution, Signature, Leadership, Artificial intelligence, Motion, Arm, Columbia University Vagelos College of Physicians and Surgeons, Humerus, SEC, Food and Drug Administration, Anatomy, Fine chemical, Dentistry, Zimmer Biomet, Trauma, Extremities, Surgeon

WARSAW, Ind., Sept. 20, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Identity Shoulder System for anatomic, reverse and revision shoulder replacement.

Key Points: 
  • WARSAW, Ind., Sept. 20, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Identity Shoulder System for anatomic, reverse and revision shoulder replacement.
  • The latest addition to Zimmer Biomet's portfolio of shoulder replacement systems, the Identity Shoulder System is designed to allow surgeons to devise and execute a patient-specific surgical plan with precision.
  • "The FDA clearance of the Identity Shoulder System is exciting because it offers surgeons a highly adaptable solution for anatomic, reverse and revision procedures to help patients optimize natural shoulder movement," said Ivan Tornos, Chief Operating Officer at Zimmer Biomet.
  • This new system expands Zimmer Biomet's upper extremities portfolio, which includes the Comprehensive Nano Stemless Shoulder and the Signature ONE Surgical Planning System, part of the ZBEdge Shoulder ecosystem.

Zimmer Biomet and Surgical Planning Associates Announce Exclusive Multi-Year Co-Marketing Agreement for HipInsight™ Mixed Reality System for Total Hip Replacement

Retrieved on: 
Thursday, September 1, 2022
ISO, Patient, NYSE, Technology, Artificial intelligence, Microsoft, Solution, Financial Planning Association of Australia, HoloLens 2, Culture, Forward-looking statement, SEC, Workflow, Innovation, U.S. Securities and Exchange Commission, Microsoft HoloLens, MD, CT scan, Surgeon, SPA, Intention, Leadership, FDA, News, Information Technology and Innovation Foundation, Twitter, Elective surgery, Private Securities Litigation Reform Act, Health, Life, Efficiency, Medical device, Zimmer Biomet

WARSAW, Ind., Sept. 1, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced an exclusive, multi-year co-marketing agreement with Surgical Planning Associates, Inc. to commercialize HipInsight, the first FDA-cleared mixed reality navigation system for total hip replacement.

Key Points: 
  • WARSAW, Ind., Sept. 1, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced an exclusive, multi-year co-marketing agreement with Surgical Planning Associates, Inc. to commercialize HipInsight, the first FDA-cleared mixed reality navigation system for total hip replacement.
  • "This collaboration enables us to offer surgeons a sophisticated and proven mixed reality-based visualization tool customized for exclusive use with our hip implant portfolio."
  • "We're proud to partner with Zimmer Biomet, a leader in joint arthroplasty, to co-market HipInsight for their portfolio of hip implant systems," said Stephen B. Murphy, M.D., founder of Surgical Planning Associates.
  • A pioneer in the fields of surgical planning and computer-assisted joint reconstruction, SPA is privately held and based in Boston.

ZimVie to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Retrieved on: 
Monday, August 29, 2022
Interest, Solution, Dental, LinkedIn, GLOBE, Instagram, Conference, Twitter, Zimmer Biomet, Life, Public relations, Spine, Facebook

WESTMINSTER, Colo., Aug. 29, 2022 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced that management will participate in Morgan Stanleys 20th Annual Global Healthcare Conference held in New York, New York.

Key Points: 
  • WESTMINSTER, Colo., Aug. 29, 2022 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced that management will participate in Morgan Stanleys 20th Annual Global Healthcare Conference held in New York, New York.
  • Vafa Jamali, President and Chief Executive Officer, and Rich Heppenstall, Chief Financial Officer, are scheduled to present onTuesday, September 13th at 7:20 AM EDT.
  • Interested parties may access a live and archived version of the webcast of the presentation at: https://investor.zimvie.com/events-presentations/event-calendar .
  • Follow @ZimVie on Twitter , Facebook , LinkedIn , or Instagram .

Orthopedic Biomaterials Market Revenue to Surpass USD 32.2 Billion by 2030, says P&S Intelligence

Retrieved on: 
Monday, August 22, 2022
Zimmer Biomet, Knee, Medtronic, Government, First Nations in Ontario, Disability, Incidence, United Nations, Fracture, Hospital, Clifton Springs Hospital & Clinic, Stryker Corporation, CAGR, Trauma, Elective surgery, Industry, Patient, Dentistry, Ceramic, Medical device, Developing country

Moreover, the improved biomaterials being offered by companies have raised the success rates of operations, encouraging more patients to go for them.

Key Points: 
  • Moreover, the improved biomaterials being offered by companies have raised the success rates of operations, encouraging more patients to go for them.
  • Get the sample pages of this report: https://www.psmarketresearch.com/market-analysis/orthopedic-biomaterials...
    Non-metallic biomaterials are more popular in orthopedics, generating almost 60% of the market revenue in 2021.
  • Hospitals & clinics are the larger end users in the orthopedic biomaterials market, with an over 40% share.
  • Moreover, almost all major market players operate in the continent, which makes advanced orthopedic biomaterials easily available.

Inspire Medical Systems, Inc. Announces Appointment of Ezgi Yagci as Vice President of Investor Relations

Retrieved on: 
Monday, August 15, 2022
FDA, Investor relations, Social, Zimmer Biomet, NYSE, GLOBE, Technology, Private Securities Litigation Reform Act, The Guardian Life Insurance Company of America, SEC, Growth, Annual report, Analysis, Conversation, Master's degree, Boston University, Patient, International relations, Bachelor, Benchmarking, Investment, Millennium Management, LLC, Financial condition report, Obstructive sleep apnea, Investor, Biophysical environment, Result, RS, Pharmaceutical industry, Management, Risk management, Inspiration, Economics

MINNEAPOLIS, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced the appointment of Ezgi Yagci as Vice President of Investor Relations, effective August 15, 2022.

Key Points: 
  • MINNEAPOLIS, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced the appointment of Ezgi Yagci as Vice President of Investor Relations, effective August 15, 2022.
  • "The team is very excited to welcome Ezgi and her vast experience in the medical technology sector to Inspire, said Tim Herbert, President and Chief Executive Officer of Inspire Medical Systems.
  • She will have a positive impact on our expanding investor relations program and play a key role in contributing to the overall strategy of the organization.
  • Ms. Yagci joins Inspire from Zimmer Biomet where she served as Investor Relations Manager since July 2020.

Paragon 28 Announces Changes to its Board of Directors

Retrieved on: 
Thursday, August 4, 2022
Biotechnology, Health, Surgery, Medical Devices, Paragon, Grace College & Seminary, ATEC, Zimmer Biomet, CEO, Recurrence, NYSE, NuVasive, Board, Chicken feet, Financial compensation, Charcot foot, Company, Corporation, Foot, FNA, NASDAQ, Certified Public Accountant, Scott, Board of directors, IRTC, Bunion, Head, Ankle, Audit committee, Management, Director, Dexcom, Accounting, IPO

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced two changes to the composition of its Board of Directors.

Key Points: 
  • Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced two changes to the composition of its Board of Directors.
  • Quentin Blackford has joined the Companys Board of Directors and will serve the Company as Chairman of its Compensation Committee and as a member of its Audit Committee.
  • We are very excited to have Quentin join our Board of Directors, said Albert DaCosta, CEO and Chairman of Paragon 28.
  • I am very grateful to Scott for his service to Paragon 28.

Roland Diggelmann Joins Mettler Toledo Board of Directors

Retrieved on: 
Monday, August 1, 2022
Smith, Food, GLOBE, MTD, Industry, Chairperson, CEO, NYSE, Quality control, Roche Diagnostics, Solution, OH, Board, Zimmer Biomet, Niece and nephew, Board of directors, Management

Columbus, OH, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Mettler-Toledo International Inc. (NYSE: MTD) announced today that Roland Diggelmann has been appointed to its Board of Directors.

Key Points: 
  • Columbus, OH, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Mettler-Toledo International Inc. (NYSE: MTD) announced today that Roland Diggelmann has been appointed to its Board of Directors.
  • Earlier in his career, Mr. Diggelmann served in various senior management roles at Zimmer Holdings, Centerpulse, and Sulzer Medica.
  • He is a member of the board of directors of Sonova Holding AG, and is a Swiss citizen.
  • Robert F. Spoerry, Chair of the Board, stated, Roland brings over 10 years of executive experience serving customers in the pharma/life science industry, a key end market for METTLER TOLEDO.

Zimmer Biomet and Hospital for Special Surgery (HSS) Announce Creation of the HSS/Zimmer Biomet Innovation Center for Artificial Intelligence in Robotic Joint Replacement

Retrieved on: 
Thursday, July 28, 2022
Magnet, Surgeon, Algorithm, Knowledge, Infection, Education, Hospital for Special Surgery, Physician, Laboratory, Data collection, Zimmer Biomet, Long Island, Twitter, ZB, Artificial intelligence, Health, CEO, NYSE, Culture, Rheumatology, Research, Solution, Innovation Center station, Weill Cornell Medicine, Nursing, News, Hospital, U.S. News & World Report, Knee, Technology, Organization, Leadership, Machine learning, HSS, MD, Ministry of Science, Technology and Innovation (Uganda), American Nurses Credentialing Center, Patient, Life, NEW, Efficiency, Therapy, Innovation, ROSA, The Hospital, AI, Medical device, Dentistry, Medicine, Newsweek, Elective surgery

WARSAW, Ind. and NEW YORK, July 28, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Hospital for Special Surgery (HSS), the world's leading academic medical center focused on musculoskeletal health, today announced a first-of-its-kind, three-year agreement to create the HSS/Zimmer Biomet (ZB) Innovation Center for Artificial Intelligence (AI) in Robotic Joint Replacement. Through the collaboration, ZB and HSS aim to develop new decision support tools, powered by data collection and machine learning, to provide data-driven recommendations to surgeons for robotic-assisted joint surgery.

Key Points: 
  • and NEW YORK, July 28, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Hospital for Special Surgery (HSS), the world's leading academic medical center focused on musculoskeletal health, today announced a first-of-its-kind, three-year agreement to create the HSS/Zimmer Biomet (ZB) Innovation Center for Artificial Intelligence (AI) in Robotic Joint Replacement.
  • "This agreement, which is our second collaboration with HSS in two years, advances our vision to accelerate impactful innovation through strategic third-party relationships."
  • "As a world leader in orthopedics, we strive to find opportunities to innovate towards improving patient care," said Michael P. Ast, MD, Chief Medical Innovation Officer at HSS.
  • "Leveraging data analytics and AI in this collaboration could enable us to improve clinical results in robotic-assisted joint replacement surgeries."